ARTICLE | Company News
Pulmokine, NIH cardiovascular news
April 7, 2014 7:00 AM UTC
Pulmokine received a contract worth up to $1.5 million from NIH's National Heart, Lung, and Blood Institute (NHLBI) to develop an inhaled platelet derived growth factor receptor (PDGFR) kinase inhibi...